New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
11:04 EDTAUXL, TKMR, KMR, SWI, TITN, BSX, NOAHActive equity options trading on open
High option volume stocks: TKMR KMR SWI TITN BSX KMI DF NOAH AMLP AUXL
News For AUXL;TKMR;KMR;SWI;TITN;BSX;NOAH From The Last 14 Days
Check below for free stories on AUXL;TKMR;KMR;SWI;TITN;BSX;NOAH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 16, 2014
17:29 EDTAUXLAuxilium up 42% following Endo acquisition proposal
16:48 EDTAUXLEndo delivers proposal to acquire Auxilium for $28.10 per share in cash, stock
Subscribe for More Information
16:48 EDTAUXLEndo delivers proposal to acquire Auxilium for $2.2B in cash, stock
Subscribe for More Information
07:58 EDTBSXBoston Scientific product still likely to get nod despite data, says Wells Fargo
Although new data presented at TCT showed that the confirmatory PREVAIL study of Boston Scientific's Watchman device missed both co-primary efficacy endpoints, Wells Fargo still thinks there is a 60%-70% chance of an FDA panel recommending approval of the device on October 8. Wells keeps an Outperform rating on the stock.
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
11:13 EDTTITNTitan Machinery management to meet with Piper Jaffray
Subscribe for More Information
07:45 EDTBSXCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
September 14, 2014
13:51 EDTAUXLAuxilium looks like 'overpriced tax shelter', Barron's says
Auxilium's (AUXL) acquisition of QLT (QLTI) for tax inversion purposes followed a collapse in Testim sales and the company "seems like an overpriced tax shelter," Barron's argues in a follow up article. Reference Link
September 12, 2014
15:03 EDTBSXSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
11:59 EDTAUXLAuxilium management to meet with Jefferies
Subscribe for More Information
September 11, 2014
10:20 EDTTKMRNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 10, 2014
10:00 EDTSWIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:23 EDTSWISolarWinds initiated with a Buy at MKM Partners
Target $50.
07:21 EDTAUXLAuxilium sees merger with QLT closing in Q4
Subscribe for More Information
September 9, 2014
17:03 EDTAUXLAuxilium announces corporate restructuring, will cut headcount approximately 30%
Subscribe for More Information
16:55 EDTAUXLAuxilium trading halted, pending news
Subscribe for More Information
09:12 EDTTITNOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTTITNTitan Machinery cuts FY15 adjusted EPS view to 30c-60c from 70c-$1.00
Subscribe for More Information
06:47 EDTTITNTitan Machinery CEO: We remain encouraged by improvement in construction
CEO David Meyer adds, "The Agriculture industry continues to face a number of headwinds, including lower projected net farm income, and lower corn and soybean prices. This has impacted farmers’ sentiment and resulted in lower farmer spending for equipment as well as more cautious spending on parts and services. While this impacted our financial results in the quarter, we remain confident in our business model as well as the long-term agriculture industry outlook as farmers continue to carry strong balance sheets and the underlying demand for commodities rebuilds. Our International business continued to face challenges, including the impact of regional flooding in Serbia and Bulgaria as well as the geopolitical turmoil in Ukraine. This resulted in lower than anticipated revenue and a larger pre-tax loss for our International segment for the quarter... Based on our year-to-date results, and outlook for the remainder of fiscal 2015, we believe our construction segment will continue to improve but we expect this improvement to be offset by continued headwinds in the Agriculture and International segments of our business.”
06:46 EDTTITNTitan Machinery reports Q2 adjusted EPS 4c, consensus 10c
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use